MORE THAN **25** YEARS OF DENTAL EXCELLENCE | | ISO 9001:2000 CERTIFIED |
A2 AASHIRWAD, II CROSS LANE, LOKHANDWALA COMPLEX, ANDHERI (WEST), MUMBAI 400053, INDIA | 2632 8682 / 3082 7053 / 98193 63215 |
DENTAL NEWS ARCHIVES 183 |
Only FDA-Approved Migraine Prevention Device Goes GlobalNTI Dental Device Now Prescribed To One Million People On Every Continent8/9/2004 MISHAWAKA, Ind. - In 1999, Dr. Jim
Boyd, a San Diego-based dentist and longtime migraine sufferer,
wondered whether nighttime jaw clenching had been overlooked as the
primary "trigger enhancer" of migraine headaches. When research bore
out his theory, he designed a tiny one-inch custom-fitted night
guard that snaps onto your two front teeth and prevents your back
teeth from clenching during sleep.
Five short years later, Dr. Boyd and his patients have not only
eliminated migraine pain from their lives, but the NTI device has
become a fast-growing medical phenomenon, becoming the country's
first migraine prevention tool to earn FDA approval, and helping
more than a million people on every continent of the globe.
Growing by an astounding 1200% over the past five years, the
device has been prescribed and fitted by 15,000 dentists globally,
and is expected to provide migraine prevention for close to a
million new patients within the next year alone (thanks in great
part to the device's new availability in China).
Twenty-three million Americans suffer from severe migraine pain
with the associated loss of productivity estimated at $17.2 billion
yearly. Eighty-two percent of migraine and headache sufferers who
use the NTI device experience an average 77% reduction of migraine
pain attacks within two months. The device is easily fit at the
dentist's office (a discreet daytime version is also available),
involves no surgery, and has no risk of side effects compared to
pharmaceutical migraine treatments.
In addition, the NTI device can be used on people who have a
history of heart attacks, strokes or heart disease. It can also be
used by pregnant women as well as people who suffer from diabetes --
all of whom can't take most major approved migraine drugs.
About NTI Source: NTI-TSS, Inc.
|